Enveric Biosciences Inc vs Palo Alto Networks Inc — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while Palo Alto Networks Inc trades at $353.82 (market cap $288.53B). The key difference: Palo Alto Networks Inc is far larger — about 54235× Enveric Biosciences Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | PANW | |
|---|---|---|
Market Cap | $5.32M | $288.53B |
Sector | Health | Technology |
52-Week High | $17.40 | $357.53 |
52-Week Low | $1.28 | $141.67 |
Enterprise Value | $408.82K | $287.49B |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Palo Alto Networks (PANW) trades at $354.65, up 0.5% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company shows strong revenue growth, reaching $9.22B in 2025, though valuation ratios like P/E of 307.84 remain elevated. Positive sentiment is driven by AI cybersecurity demand, with news highlighting sector rallies and platform expansion strategies.
Outlook: Growth prospects are solid amid AI-driven security spending, but high valuations and integration costs pose risks. Analyst consensus is bullish with a $339.56 price target, though competition and margin pressures require monitoring for sustained shareholder value.
Trailing returns across standard periods
Latest headlines on both assets
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →